Αποτελέσματα Αναζήτησης
19 Ιουν 2024 · With a primary endpoint of 5-year iDFS, the investigators were able to demonstrate considerable improvements to iDFS for those on a trastuzumab-containing regimen (AC-TH or TCH).
Our results suggest neoadjuvant pertuzumab based regimens confer superior pCR rates with similar tolerability compared to AC-TH. The observed pCR rates align with results observed in TRYPHAENA. In TRYPHAENA, the pCR rate for FEC-THP was 54.7%, while we observed a pCR rate of 60% for dose-dense AC-THP.
8 Ιαν 2015 · The 3-year rate of survival free from invasive disease was 98.7% (95% confidence interval [CI], 97.6 to 99.8). Among the 12 relapses seen, 2 were due to distant metastatic breast cancer.
6 Οκτ 2011 · The estimated disease-free survival rates at 5 years were 75% among patients receiving AC-T, 84% among those receiving AC-T plus trastuzumab, and 81% among those receiving TCH.
1 Σεπ 2022 · The 7-year overall survival rate was 95.9% (95% CI: [95.0–96.6%) and the 7-year time-to-distant recurrence was 93.4% (95% CI: 92.3–94.4%).
8 Οκτ 2014 · This study revealed that four cycles of TC is superior to AC in both DFS and OS. 24 Elderly women (>65 years) constituted 16% of the study population, and ~90% of women had node-negative or one to three node-positive early breast cancer.
With pCR as the primary endpoint, the combination of chemotherapy plus dual HER2-targeting agents achieved a pCR rate in breast (ypT0/is) of 45.8%, compared with 29% for trastuzumab and docetaxel, 24% for pertuzumab and docetaxel, and 16.8% for dual HER2 blockade without chemotherapy (P=.0141).
